Fruquin 5mg (Fruquintinib) – Targeted Therapy for mCRC
Fruquin 5mg (Fruquintinib) is an advanced oral targeted therapy used for adult patients with metastatic colorectal cancer (mCRC) who have already been treated with standard chemotherapy and earlier targeted options. Designed to inhibit tumor angiogenesis, FRUQUIN 5 mg helps control cancer progression when limited treatment alternatives remain.
This once-daily oral treatment offers convenience, precision, and clinically proven benefits for patients who require a late-line therapy that supports longer disease control and improved outcomes.
What Is Fruquin 5mg Indicated For?
FRUQUIN 5 mg is recommended for adult patients diagnosed with metastatic colorectal cancer, specifically when:
- The disease has spread to distant organs (liver, lungs, lymph nodes, etc.)
- Standard chemotherapy (e.g., fluoropyrimidines, oxaliplatin, irinotecan) has stopped working
- Previous targeted therapy regimens are no longer effective
- Disease continues to progress and new treatment options are required
As a third-line or later-line therapy, FRUQUIN 5 mg is typically prescribed when other available treatments have been exhausted.
How Fruquin 5mg Works (Mechanism of Action)
FRUQUIN 5 mg is a potent and highly selective VEGFR inhibitor that blocks the signaling pathways responsible for tumor blood vessel formation.
Therapeutic Actions:
- Inhibits VEGFR-1, VEGFR-2, and VEGFR-3
- Prevents new blood vessels from forming (anti-angiogenesis)
- Reduces oxygen and nutrient supply to cancer cells
- Suppresses tumor growth and limits metastasis
- Helps slow disease progression in late-stage cancer
Instead of killing cancer cells directly, Fruquintinib starves the tumor, making it highly effective for cancers that are difficult to treat in later stages.
Recommended Dosage & How to Take Fruquin 5mg
- Dose: 5 mg orally
- Frequency: Once daily
- Treatment Cycle: Commonly 3 weeks on treatment + 1 week off (as instructed by the oncologist)
- Administration:
- Can be taken with or without food
- Take at the same time each day
- Swallow capsules whole; do not crush or chew
Do NOT adjust, skip, or stop treatment without medical advice.
If You Miss a Dose
- Take it as soon as you remember on the same day
- Skip it completely if the next dose is near
- Do NOT double the dose
Side Effects of Fruquin 5mg (Fruquintinib)
Like all targeted therapies, FRUQUIN 5 mg may cause side effects. Most are manageable with supportive care and regular monitoring.
Common Side Effects:
- Fatigue and weakness
- Loss of appetite
- High blood pressure (hypertension)
- Diarrhea or constipation
- Mouth sores
- Hand-foot skin reaction (HFSR)
- Abdominal pain
- Hoarseness or voice changes
- Low blood counts (neutropenia, anemia)
- Protein in urine
- Elevated liver enzymes
Less Common but Serious Side Effects:
- Severe hypertension
- Gastrointestinal perforation
- Liver dysfunction
- Heart complications
- Impaired wound healing
- Risk of bleeding
Seek medical attention immediately if you experience chest pain, severe headache, abnormal bleeding, or signs of infection (fever, chills).
Monitoring Requirements During Treatment
Your oncologist may recommend regular tests such as:
- Blood pressure monitoring
- Complete blood count (CBC)
- Liver function tests
- Urine protein tests
- Electrolyte levels
- Tumor imaging scans
Monitoring ensures the dose is safe and effective throughout therapy.
Precautions & Safety Advice
Before taking FRUQUIN 5 mg, inform your physician if you:
- Have high blood pressure
- Have heart, kidney, or liver issues
- Recently had surgery or have wounds
- Are pregnant, breastfeeding, or planning pregnancy
- Are taking blood thinners or other targeted drugs
Pregnancy & Breastfeeding
Fruquintinib may cause harm to unborn babies.
Effective contraception is required during treatment and for some time after completion.
Storage & Handling
- Store at 25°C (77°F)
- Keep in original packaging to protect from moisture
- Do not expose to direct sunlight
- Keep out of reach of children
- Do not use expired medication
Why Patients Choose Fruquin 5mg
- Convenient at-home oral therapy
- Highly selective VEGFR inhibition
- Designed for late-line treatment
- Helps delay disease progression
- Suitable when other options fail
FRUQUIN 5 mg offers renewed hope for patients with advanced mCRC who require a reliable and targeted approach to managing their disease.
Reviews
There are no reviews yet.